A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma
Recruiting · Phase 4 · NCT06876662
Conditions: Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma
At a glance
- Research payments reported, 2025
- $613,771
- U.S. investigators named
- 14
- Sites paid
- 15
- Planned or actual enrollment
- 279
About the trial
- Sponsor
- Eli Lilly and Company
- Tested
- Pirtobrutinib (drug)
- Dates
- Started 2025-05-20; completion 2032-12
- Results posted
- Not yet
Study J2N-MC-JZ01 (JZ01) is an individual-study appendix (ISA) under master protocol J2N-MC-JZNY, and represents participants from the completed originator study, clinical study LOXO-BTK-18001/J2N-OX-JZNA. Participants in the originator study will have the opportunity to continue their assigned study intervention or continue their follow-up visits by transitioning to this study. This study will evaluate the long-term safety and efficacy of pirtobrutinib.
From ClinicalTrials.gov, last updated 2026-03-02. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Eli Lilly and Company reported $613,771 in research payments for this study in 2025 (15 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Manish R. Patel, MD Medical Oncology · Sarasota, FL
- Jonathon B. Cohen, M.D. Hematology & Oncology · Atlanta, GA
- Shuo Ma, M.D., PH.D. Hematology & Oncology · Chicago, IL
- Jennifer R. Brown, MD PHD Hematology · Boston, MA
- Yucai Wang, MD, PHD Hematology & Oncology · Rochester, MN
- Prioty Islam, MD Internal Medicine · Concord, NC
- Matthew S. Mckinney, M.D. Hematology & Oncology · Durham, NC
- Matthew A. Lunning, D.O. Medical Oncology · Omaha, NE
- Steven Allen Hematology & Oncology · Lake Success, NY
- Jennifer A. Woyach, MD Hematology · Columbus, OH
- Sunita D. Nasta, MD Hematology & Oncology · Philadelphia, PA
- Nirav R. Shah, MD, MPH Gastroenterology · Wyomissing, PA
- Luhua M. Wang, M.D. Hematology & Oncology · Houston, TX
- Swathi Namburi, MD Hematology & Oncology · Seattle, WA
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Memorial Sloan-Kettering $122,140
- Medical College of Wisconsin Inc $61,216
- Sarah Cannon Research Institute LLC $55,065
- Ut MD Anderson Cancer Center $52,392
- Biomedical Research Alliance of New York $47,447
- Swedish Issaquah, WA $39,931
- Dana Farber PArtners Cancer Care Inc $34,641
- Florida Cancer Specialists $33,407
- The Ohio State University $33,182
- Mayo Clinic $31,639
- Hospital of Univ of Pennsylvania, PA $30,005
- Duke University $26,652
- Unehealth $19,678
- Emory University Hospital, GA $15,229
- Northwestern University $11,148
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.